Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| Business Activity | PASS |
| Debt Ratio (0.30%) | PASS |
| Cash Ratio (0.00%) | PASS |
| Receivables Ratio (0.38%) | PASS |
| Revenue Ratio (0.01%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | 1.45 | Pending | — |
| 2026-05-06 | 1.19 | 1.42 | +19.3% |
| 2026-02-18 | 1.46 | 1.55 | +6.0% |
| 2025-11-06 | 1.15 | 1.24 | +8.1% |
| 2025-08-07 | 0.92 | 1.17 | +26.8% |
| 2025-05-08 | 0.79 | 1.02 | +29.7% |
| 2025-02-20 | 1.02 | 1.15 | +12.6% |
| 2024-11-07 | 0.76 | 0.90 | +18.3% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $761.7M | $91.1M | $153.9M | $529.1M | $122.2M | 1.30 |
| 2025-12-31 | $783.8M | $101.6M | $179.5M | $568.6M | $146.3M | 1.44 |
| 2025-09-30 | $706.3M | $87.6M | $160.4M | $510.1M | $117.7M | 1.24 |
| 2025-06-30 | $649.1M | $22.5M | $70.3M | $452.2M | $121.1M | 0.32 |
| 2025-03-31 | $569.0M | $35.4M | $79.1M | $409.0M | $88.7M | 0.50 |
| 2024-09-30 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-20 | HOPFIELD JESSICA | Director | 1,660 | — |
| 2026-05-20 | HUFFINES ROBERT LUTHER | Director | 1,660 | — |
| 2026-05-20 | FREDERICK WAYNE A.I. | Director | 1,660 | — |
| 2026-05-20 | MINOGUE MICHAEL R | Director | 1,660 | — |
| 2026-04-01 | PANOS MICHAEL | Officer | 2,777 | — |
| 2026-03-31 | HUFFINES ROBERT LUTHER | Director | 111 | $23.3K |
| 2026-02-25 | MINOGUE MICHAEL R | Director | 2,030 | $499.8K |
| 2026-02-24 | KAPPLES JOHN W. | General Counsel | 1,885 | — |
| 2026-02-24 | BENJAMIN ERIC | Chief Operating Officer | 3,822 | — |
| 2026-02-24 | MCEVOY ASHLEY | Chief Executive Officer | 10,046 | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 6.4M | $987.4M | 0.1% |
| Vanguard Capital Management LLC | 4.6M | $709.2M | 0.1% |
| FMR, LLC | 4.0M | $615.6M | 0.1% |
| Vanguard Portfolio Management LLC | 3.4M | $534.3M | 0.0% |
| State Street Corporation | 3.0M | $471.2M | 0.0% |
| BAILLIE GIFFORD & CO | 2.0M | $314.3M | 0.0% |
| Geode Capital Management, LLC | 2.0M | $313.7M | 0.0% |
| T. Rowe Price Investment Management, Inc. | 1.8M | $281.2M | 0.0% |
| Capital Research Global Investors | 1.7M | $258.6M | 0.0% |
| AQR Capital Management, LLC | 1.6M | $247.6M | 0.0% |
Buy
Hold
Sell
Strong Sell
$11.3B
7.19
1.197
24
$2.9B
$1.0B
+159.0%
1.52
2.82
0.0%
5,400
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $1.45 | Pending | — |
| 2026-05-06 | $1.19 | $1.42 | +19.3% |
| 2026-02-18 | $1.46 | $1.55 | +6.0% |
| 2025-11-06 | $1.15 | $1.24 | +8.1% |
| 2025-08-07 | $0.92 | $1.17 | +26.8% |
| 2025-05-08 | $0.79 | $1.02 | +29.7% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($246.79, 24 analysts) | |||
| 10 | $1,487.85 | +$980.10 (66%) | 4.4R |
| 50 | $7,439.25 | +$4,900.50 (66%) | 4.4R |
| 100 | $14,878.50 | +$9,801.00 (66%) | 4.4R |
| To Fair Value ($241.94) | |||
| 10 | $1,487.85 | +$931.60 (63%) | 4.2R |
| 50 | $7,439.25 | +$4,658.00 (63%) | 4.2R |
| 100 | $14,878.50 | +$9,316.00 (63%) | 4.2R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ISRG | 0.397 |
| BGSI | 0.368 |
| SYK | 0.365 |
| ADJEX | 0.348 |
| TECH | 0.347 |
| Ticker | Correlation |
|---|---|
| 2269.T | -0.247 |
| 2223.SR | -0.188 |
| HEKTAR.KL | -0.151 |
| GFH.KW | -0.148 |
| 0688.HK | -0.144 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500